RedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23

Read More »

RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.

Read More »

RedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59

Read More »

RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.

Read More »

RedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.

Read More »

RedHill Biopharma Ltd.: Strategic Expansion from R&D to Sales of Drugs in the US

Read More »

RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59

Read More »

RedHill Biopharma: Net revenues for Q1-18 are lower than estimated; RedHill will have to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; target price remains at NIS 2.59

Read More »

RedHill Biopharma Ltd.: The Strategic Expansion and Clinical Progress are in line with the Company’s plans. Stock Target Price Unchanged.

Read More »